Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
Journal of Clinical Investigation · 01.10.2024 · 134 (19)
DOI: 10.1172/jci178604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 13.08.2024. Verfasst von Xiaolin Zhu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Drug Resistance, Neoplasm, Signal Transduction. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Prostate Cancer Foundation, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND Androgen receptor signaling inhibitors (ARSIs) have improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), but their clinical benefit is limited by treatment resistance. METHODS To investigate the mechanisms of ARSI resistance, we analyzed the whole-genome ( n = 45) and transcriptome ( n = 31) sequencing data generated from paired metastatic biopsies obtained before initiation of first-line ARSI therapy for mCRPC and after radiographic disease progression. We investigated the effects of genetic and pharmacologic modulation of SSTR1 in 22Rv1 cells, a representative mCRPC cell line. RESULTS We confirmed the predominant role of tumor genetic alterations converging on augmenting androgen receptor (AR) signaling and the increased transcriptional heterogeneity and lineage plasticity during the emergence of ARSI resistance. We further identified amplifications involving a putative enhancer downstream of the AR and transcriptional downregulation of SSTR1 , encoding somatostatin receptor 1, in ARSI-resistant tumors. We found that patients with SSTR1 -low mCRPC tumors derived less benefit from subsequent ARSI therapy in a retrospective cohort. We showed that SSTR1 was antiproliferative in 22Rv1 cells and that the FDA-approved drug pasireotide suppressed 22Rv1 cell proliferation. CONCLUSION Our findings expand the knowledge of ARSI resistance and point out actionable next steps, exemplified by potentially targeting SSTR1, to improve patient outcomes. FUNDING National Cancer Institute (NCI), NIH; Prostate Cancer Foundation; Conquer Cancer, American Society of Clinical Oncology Foundation; UCSF Benioff Initiative for Prostate Cancer Research; Netherlands Cancer Institute.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.
- Division of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, California, USA.
- Department of Radiation Oncology, UCSF, San Francisco, California, USA.
- Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
- Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands.
Förderung
- NCI NIH HHS
- Prostate Cancer Foundation
- National Cancer Institute
Zitieren
APA
Zhu, X., Farsh, T., Vis, D., Yu, I., Li, H., Liu, T., Sjöström, M., Shrestha, R., Kneppers, J., Severson, T., Zhang, M., Lundberg, A., Moreno Rodriguez, T., Weinstein, A. S., Foye, A., Mehra, N., Aggarwal, R. R., Bergman, A. M., Small, E. J., …, & Feng, F. Y. (2024). Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation, 134(19). https://doi.org/10.1172/jci178604
Vancouver
Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, et al. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation. 2024;134(19). doi:10.1172/jci178604
BibTeX
@article{Zhu2024,
author = {Zhu, Xiaolin and Farsh, Tatyanah and Vis, Daniël and Yu, Ivan and Li, Haolong and Liu, Tianyi and Sjöström, Martin and Shrestha, Raunak and Kneppers, Jeroen and Severson, Tesa and Zhang, Meng and Lundberg, Arian and Moreno Rodriguez, Thaidy and Weinstein, Alana S and Foye, Adam and Mehra, Niven and Aggarwal, Rahul R and Bergman, Andries M and Small, Eric J and Lack, Nathan A and Zwart, Wilbert and Quigley, David A and van der Heijden, Michiel S and Feng, Felix Y},
title = {Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {19},
doi = {10.1172/jci178604}
}
EUVIMED